Publication at Faculty of Medicine in Pilsen |
2015
Abstract
Microinflammation is an inevitable characteristic of inner millieau in patients with chronic kidney disease. It probably acts as a catalyser and increases mortality by mechanisms orelated to activating inflammatory cascade.
Strategies reducing biomarkers of microinflammation are e.g. administration of tocoferrol, isoflavones, catechines, N-acetyl cystein, cholecalciferrol, sevelamer, some statins and biological agens as e.g. etanercept.